Gritstone Oncology is a biotechnology company based in Cambridge, MA, dedicated to developing innovative immunotherapies for cancer and infectious diseases. Their approach involves harnessing the power of the patient's immune system to recognize and eliminate tumors or virally infected cells, using artificial intelligence-driven platforms to identify T cell targets and unique delivery systems to stimulate the immune response. With a focus on tumor-specific neoantigens and personalized cancer vaccines, Gritstone aims to extend the benefits of immunotherapy to a wider range of patients.
Through their research and development efforts, Gritstone is also working on next-generation vaccines for infectious diseases, including a collaboration with Gilead Sciences to develop a vaccine-based immunotherapy for HIV infection. Their goal is to create more potent and durable immune responses against diseases like COVID-19 and other common viral infections. With facilities in Pleasanton, CA, Emeryville, CA, and Cambridge, MA, Gritstone is equipped with state-of-the-art labs and manufacturing capabilities to support their innovative immunotherapy platforms.
Generated from the website